Meeting News

Roclatan maintains IOP-lowering effect at 1 year

NEW YORK — A once-daily fixed dose of Roclatan for patients with ocular hypertension or open-angle glaucoma demonstrated statistically significant IOP lowering compared with the drug’s individual components, according to a poster presented here of the 12-month data of the Mercury 1 study.

“This study demonstrated superiority at all nine time points up to the primary efficacy endpoint at month 3. It continued to maintain IOP lowering all the way to month 12,” Theresa Heah, MD, a co-author of the study, told Healio.com/OSN.

The Mercury 1 study was a randomized, 12-month, phase 3 study of patients treated with Roclatan (netarsudil 0.02% and latanoprost ophthalmic solution 0.005%, Aerie Pharmaceuticals) compared with patients treated with its individual components. Patients with maximum baseline IOP between 20 mm Hg and 36 mm Hg were included in the study.

Roclatan had previously shown superiority at all time points over its individual components for IOP lowering, but at 12 months, a significantly greater proportion of patients randomized to Roclatan achieved a mean diurnal IOP of 18 mm Hg or less than patients who received Rhopressa (netarsudil 0.02%, Aerie) or latanoprost. According to the study, 82% of Roclatan patients achieved an IOP of 18 mm Hg or less compared with 57% of patients who received netarsudil and 68% of patients who received latanoprost.

Data from Mercury 1 show Roclatan to have a consistent safety profile over 12 months of treatment, Heah noted. by Robert Linnehan

 

Reference:

Brubaker J, et al. Once-daily fixed-dose combination of netarsudil 0.02% and latanoprost 0.005% in ocular hypertension/open-angle glaucoma: 12-month data from Mercury-1. Presented at: American Glaucoma Society annual meeting; Feb. 28 to March 4, 2018; New York.

Disclosure: Heah reports she is vice president of clinical research and medical affairs for Aerie Pharmaceuticals.

NEW YORK — A once-daily fixed dose of Roclatan for patients with ocular hypertension or open-angle glaucoma demonstrated statistically significant IOP lowering compared with the drug’s individual components, according to a poster presented here of the 12-month data of the Mercury 1 study.

“This study demonstrated superiority at all nine time points up to the primary efficacy endpoint at month 3. It continued to maintain IOP lowering all the way to month 12,” Theresa Heah, MD, a co-author of the study, told Healio.com/OSN.

The Mercury 1 study was a randomized, 12-month, phase 3 study of patients treated with Roclatan (netarsudil 0.02% and latanoprost ophthalmic solution 0.005%, Aerie Pharmaceuticals) compared with patients treated with its individual components. Patients with maximum baseline IOP between 20 mm Hg and 36 mm Hg were included in the study.

Roclatan had previously shown superiority at all time points over its individual components for IOP lowering, but at 12 months, a significantly greater proportion of patients randomized to Roclatan achieved a mean diurnal IOP of 18 mm Hg or less than patients who received Rhopressa (netarsudil 0.02%, Aerie) or latanoprost. According to the study, 82% of Roclatan patients achieved an IOP of 18 mm Hg or less compared with 57% of patients who received netarsudil and 68% of patients who received latanoprost.

Data from Mercury 1 show Roclatan to have a consistent safety profile over 12 months of treatment, Heah noted. by Robert Linnehan

 

Reference:

Brubaker J, et al. Once-daily fixed-dose combination of netarsudil 0.02% and latanoprost 0.005% in ocular hypertension/open-angle glaucoma: 12-month data from Mercury-1. Presented at: American Glaucoma Society annual meeting; Feb. 28 to March 4, 2018; New York.

Disclosure: Heah reports she is vice president of clinical research and medical affairs for Aerie Pharmaceuticals.

    See more from American Glaucoma Society Meeting